Compare · IDXG vs MMM
IDXG vs MMM
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $94.90B, about 4091.0x IDXG ($23.2M).
- MMM has been more active in the news (7 items in the past 4 weeks vs 3 for IDXG).
- MMM has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- 3M Company
- Price
- -
- -
- Market cap
- $23.2M
- $94.90B
- 1M return
- -
- +11.15%
- 1Y return
- -
- +11.10%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 3
- 7
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest IDXG
- SEC Form CERT filed by Interpace Biosciences, Inc.
- SEC Form 8-A12B filed by Interpace Biosciences, Inc.
- Amendment: SEC Form S-1/A filed by Interpace Biosciences, Inc.
- SEC Form FWP filed by Interpace Biosciences, Inc.
- SEC Form 8-K filed by Interpace Biosciences, Inc.
- Amendment: SEC Form S-1/A filed by Interpace Biosciences, Inc.
- SEC Form S-1 filed by Interpace Biosciences, Inc.
- SEC Form S-8 filed by Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: Interpace Biosciences, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest MMM
- 3M downgraded by Wolfe Research
- The Dow Rallies Back Above a Key Average, but Five Charts Made Even Bigger Moves Today
- 3M Reaches Broad Resolution of AFFF Personal Injury Litigation
- 3M Board Approves New $6 Billion Share Repurchase Authorization, Declares Quarterly Dividend
- Meguiar’s® Reveals Ford F-100 & Aston Martin GT3 in its 2026 SEMA Booth
- EVP Chief Strategy Officer Van Wyck Jonathan G. exercised 1,501 shares at a strike of $174.34 and covered exercise/tax liability with 460 shares, increasing direct ownership by 400% to 1,302 units (SEC Form 4)
- Meguiar’s® Unleashes a Trove of New 2027 Car Care Products: Continuing 125 Years of Innovation!
- 3M and AWS collaborate to advance optical connectivity innovation
- Outside Big Tech, Tuesday's Earnings Winners Jumped as Much as 11%
- SEC Form 10-Q filed by 3M Company